NDARECTALAEROSOL, METERED
Approved
Feb 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
CORTIFOAM (hydrocortisone acetate) by Viatris (2) is clinical pharmacology cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. First approved in 1982.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cortifoam is a metered-dose rectal aerosol formulation of hydrocortisone acetate, a topical corticosteroid approved in 1982. It delivers anti-inflammatory therapy directly to the rectum for adjunctive treatment of ulcerative proctitis, with studies showing penetration approximately 10 centimeters into the rectal vault. The drug works by reducing inflammation and immune response in the distal colon and rectum.
$0.528MPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D spending (~$528K in 2023), indicating a niche market with limited commercial team expansion opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Direct observations of methylene blue-containing foam have shown staining about 10 centimeters into the rectum.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
Started Mar 2016
16 enrolled
Healthy
Career Relevance
Working on Cortifoam offers limited career growth opportunities given the product's niche market, approaching LOE status, and absence of clinical development activities. This role is best suited for professionals seeking stability in a mature product or transitional roles before eventual generic conversion.
Brand Manager
Worked on CORTIFOAM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.